研報掘金|華興證券:上調藥明生物目標價至33.4港元 未來有望實現穩健增長
華興證券發表報告指,藥明生物2024年公司業績符合預期,未來有望實現穩健增長。根據公司2024年報告,2014至2024年公司非新冠收入覆合增長率超過50%。隨着生產工藝持續優化和效率不斷提升,以及全球佈局的進一步完善,公司預計2025年收入有望實現按年增長12%-15%。該行預計,公司2025至2027年收入與利潤將保持上升趨勢,分別爲13.4%、18.9%、18.4%和10.7%、18.6%及16.7%,目標價由26.12港元上調至33.4港元,重申“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.